Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risk of hypocalcemia with first-time Pralia (denosumab) in rheumatoid arthritis: MID-NET cohort study
jRCT1080224168Unknown
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Dec 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of denosumab in rheumatoid arthritis (RA) and osteoporosis (2 cohorts), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Risk of hypocalcemia in Pralia-treated rheumatoid arthritis patients. Status: unknown.
02
Drugs
denosumab
03
Conditions
rheumatoid arthritis (RA)osteoporosis
Beyond the preview
Go deeper on jRCT1080224168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080224168.